Mobia Medical (Nasdaq: MOBI) announced that implantable paired Vagus Nerve Stimulation (VNS) has been included in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery from the American Heart Association and American Stroke Association as a treatment option to improve upper-limb function and impairment in eligible chronic stroke survivors.
The guideline notes that VNS should be paired with high-dose, task-specific training. According to Mobia Medical, its Vivistim® Paired VNS™ System is currently the only FDA-approved system delivering this approach, aligning with updated guidance that emphasizes continuity of care, intensive task-specific therapy, and patient-specific functional outcomes.
Mobia Medical (Nasdaq: MOBI) reported second quarter 2026 revenue of $13.5 million, up 102% from $6.7 million a year earlier, driven by higher adoption of the Vivistim System. Gross profit rose to $11.2 million, with gross margin at 83.2% versus 82.3% in 2025.
Operating expenses increased 83% to $29.2 million, leading to a net loss of $21.0 million, or $1.10 per share, compared to a $10.5 million loss, or $12.44 per share, in the prior-year quarter. Cash and cash equivalents were $177.1 million, reflecting approximately $134.0 million in net IPO proceeds received in May 2026.
For full year 2026, the company expects revenue of $54.0–$56.0 million, implying 69%–75% growth over 2025. Mobia Medical also highlighted publication of two-year VNS-REHAB follow-up data and new board appointments bringing additional medtech and clinical expertise.
Mobia Medical (Nasdaq: MOBI) appointed Myriam Curet, M.D. to its Board of Directors as an independent director, effective July 30, 2026. The company highlights her combination of clinical, executive and public company board experience to support its stroke recovery business.
Dr. Curet is a Clinical Professor of Surgery at Stanford University School of Medicine, holds a part-time clinical role at the Palo Alto VA Medical Center, and has previously held senior surgical posts at Stanford and the University of New Mexico. She also serves on the boards of Inspire Medical Systems (NYSE: INSP) and Stereotaxis (NYSE American: STXS) and is a Fellow of the American College of Surgeons.
Mobia Medical (Nasdaq: MOBI) announced it will report its second quarter 2026 financial results on Tuesday, August 11, 2026. Management will host a conference call and webcast at 4:30 p.m. ET the same day to review results and provide a corporate update. Investors must register online in advance to receive dial-in details and a unique PIN, while a live and archived webcast will be available on the News & Events page of the company’s investor website.
Mobia Medical (Nasdaq: MOBI) appointed Reza Zadno, Ph.D., as an independent member of its Board of Directors, effective July 14, 2026. He will also serve on the company’s Compensation Committee.
According to Mobia Medical, Dr. Zadno brings over 35 years of medical technology experience, including leadership roles as President and CEO at PROCEPT BioRobotics, where he led the 2021 IPO, and at Avedro prior to its acquisition by Glaukos. He has also served on the boards and audit committees of several public healthcare companies, including Invuity and Carbylan Therapeutics. Dr. Zadno cited Mobia’s Vivistim Therapy and its mission in stroke recovery as key reasons for joining the Board.
Mobia Medical (Nasdaq: MOBI) reported two-year follow-up results from the pivotal VNS-REHAB trial of its Vivistim® Paired VNS™ Therapy, now published in Neurology. Among 49 chronic ischemic stroke survivors, 76% achieved a clinically meaningful response on the Fugl-Meyer Assessment of Upper Extremity impairment (FMA-UE) and/or the Wolf Motor Function Test (WMFT).
Participants showed an average FMA-UE improvement of +7.5 points from baseline (exceeding the ≥6-point MCID) and an average WMFT improvement of +0.63 (above the ≥0.4-point MCID). These gains were accompanied by statistically significant, clinically meaningful improvements in activities of daily living, hand and arm use, and stroke-specific quality of life. Three-year follow-up data from 16 participants suggest benefits can be durable long term, and some patients improved further between years one and two. No long-term serious therapy- or stimulation-related adverse events were reported through two years.
Mobia Medical (Nasdaq:MOBI) announced that CMS has proposed keeping CPT® Code 64568 for the Vivistim procedure in New Technology APC 1580 for calendar year 2027, with an estimated hospital outpatient payment of about $45,000, unchanged from 2026.
CMS expects to finalize the OPPS rule in November 2026, with any changes effective January 1, 2027. Mobia Medical views the proposed continuity in reimbursement as supportive of hospitals expanding Vivistim programs and Medicare beneficiary access.
Mobia Medical (Nasdaq: MOBI) priced an initial public offering of 10,000,000 common shares at $15.00 per share, implying gross proceeds of approximately $150.0 million before underwriting discounts, commissions, and offering expenses. Trading on the Nasdaq Global Select Market under MOBI is expected to begin on May 8, 2026, and the offering is expected to close on May 11, 2026, subject to customary closing conditions. Underwriters have a 30-day option to purchase up to an additional 1,500,000 shares at the IPO price less underwriting discounts.